New Vaxzevria data further support its use as third dose booster.
The results were observed among individuals previously vaccinated with either Vaxzevria or an mRNA vaccine. A separate Phase IV trial reported in a preprint with The Lancet on SSRN showed that a third dose of Vaxzevria substantially increased antibody levels following a primary vaccine series with CoronaVac (Sinovac Biotech). These data add to the growing body of evidence supporting Vaxzevria as a third dose booster irrespective of the primary vaccination schedules tested. The Company is submitting these additional data to health authorities around the world given the urgent need for third dose boosters.
See-Costa Clemens SA, et al. "Randomized immunogenicity and safety study of heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 Vaccine". Preprint 2021. Available at SSRN: https://ssrn.com/abstract=3989848 [Last accessed: January 2022]. Preprints with The Lancet available via the SSRN platform are not Lancet publications and have not been peer-reviewed.